Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Astellas Pharma Inc. logo
4503.T
Astellas Pharma Inc.
06:30:00
2145.5 ¥
0.0000 (%0.00)
Previous Close: 2175
Day Low₺2122
Day High₺2161
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

4503.T: Astellas Pharma Inc. Financials

Astellas Pharma Inc. Income Statement

Total revenue
Net income
Gross margin TTM
74.55%
Operating margin TTM
19.62%
Net profit margin TTM
13.63%
Return on investment TTM
15.92%
Period end31/03/202631/03/202531/03/202431/03/2023
Total revenue2,139,245,000,0001,912,323,000,0001,603,672,000,0001,518,619,000,000
Operating income419,698,000,000255,672,000,000178,070,000,000285,430,000,000
Net income291,535,000,00050,747,000,00017,045,000,00098,714,000,000

All line items

Line item31/03/202631/03/202531/03/202431/03/2023
Total revenue2,139,245,000,0001,912,323,000,0001,603,672,000,0001,518,619,000,000
Cost of revenue544,408,000,000349,206,000,000292,485,000,000288,353,000,000
Gross profit1,594,837,000,0001,563,117,000,0001,311,187,000,0001,230,266,000,000
Research and development expenses314,827,000,000327,700,000,000294,200,000,000276,100,000,000
General and administrative expenses0000
Selling and marketing expenses0000
Selling, general and administrative expenses860,312,000,000843,032,000,000740,110,000,000630,272,000,000
Other expenses0136,713,000,00098,807,000,00038,464,000,000
Operating expenses1,175,139,000,0001,307,445,000,0001,133,117,000,000944,836,000,000
Cost and expenses1,719,547,000,0001,656,651,000,0001,425,602,000,0001,233,189,000,000
Net interest income-6,046,000,000-9,803,000,000-596,000,000-669,000,000
Interest income8,026,000,0007,874,000,0008,772,000,0008,110,000,000
Interest expense14,072,000,00017,677,000,0009,368,000,0008,779,000,000
Depreciation and amortization194,594,000,000199,132,000,000157,840,000,000105,738,000,000
EBITDA585,253,000,000462,672,000,000282,446,000,000337,390,000,000
EBIT390,659,000,000263,540,000,000124,606,000,000231,652,000,000
Non-operating income (excl. interest)29,039,000,000-7,868,000,00053,464,000,00053,778,000,000
Operating income419,698,000,000255,672,000,000178,070,000,000285,430,000,000
Total other income/expenses (net)-43,111,000,000-224,435,000,000-153,101,000,000-153,069,000,000
Income before tax376,587,000,00031,237,000,00024,969,000,000132,361,000,000
Income tax expense85,013,000,000-19,510,000,0007,924,000,00033,647,000,000
Net income from continuing operations291,574,000,00050,747,000,00017,045,000,00098,714,000,000
Net income from discontinued operations0000
Other adjustments to net income1,000,000000
Net income291,535,000,00050,747,000,00017,045,000,00098,714,000,000
Net income deductions0000
Bottom line net income291,535,000,00050,747,000,00017,045,000,00098,714,000,000
EPS163281054
Diluted EPS16228954
Weighted average shares outstanding1,791,105,0001,790,205,0001,793,276,0001,820,019,000
Weighted average diluted shares outstanding1,797,116,0001,797,159,0001,799,660,0001,825,061,000

Astellas Pharma Inc. Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
320,000,000,000%
Total debt / assets MRQ
—
Period end31/03/202631/03/202531/03/202431/03/2023
Total assets3,567,042,000,0003,339,544,000,0003,569,603,000,0002,456,518,000,000
Total liabilities1,736,158,000,0001,826,290,000,0001,973,616,000,000948,564,000,000
Total equity1,830,884,000,0001,513,255,000,0001,595,988,000,0001,507,954,000,000

All line items

Line item31/03/202631/03/202531/03/202431/03/2023
Cash and cash equivalents281,605,000,000188,372,000,000335,687,000,000376,840,000,000
Short-term investments0000
Cash and short-term investments281,605,000,000188,372,000,000335,687,000,000376,840,000,000
Net receivables761,763,000,000646,216,000,000548,036,000,000445,778,000,000
Accounts receivable746,808,000,000632,525,000,000534,985,000,000427,965,000,000
Other receivables14,955,000,00013,691,000,00013,051,000,00017,813,000,000
Inventory331,014,000,000297,261,000,000248,738,000,000174,386,000,000
Prepaid expenses0000
Other current assets47,541,000,00069,500,000,00062,269,000,00052,950,000,000
Total current assets1,421,923,000,0001,201,349,000,0001,194,730,000,0001,049,954,000,000
Property, plant and equipment (net)358,424,000,000328,921,000,000293,742,000,000286,459,000,000
Goodwill441,175,000,000415,207,000,000418,694,000,000328,411,000,000
Intangible assets996,932,000,0001,123,714,000,0001,453,824,000,000562,496,000,000
Goodwill and intangible assets1,438,107,000,0001,538,921,000,0001,872,518,000,000890,907,000,000
Long-term investments158,593,000,000143,637,000,000144,421,000,000134,748,000,000
Tax assets146,588,000,00098,113,000,00045,594,000,00084,169,000,000
Other non-current assets43,407,000,00028,603,000,00018,598,000,00010,281,000,000
Total non-current assets2,145,119,000,0002,138,195,000,0002,374,873,000,0001,406,564,000,000
Other assets0000
Total assets3,567,042,000,0003,339,544,000,0003,569,603,000,0002,456,518,000,000
Total payables268,686,000,000121,586,000,000223,708,000,000145,373,000,000
Accounts payable199,752,000,00087,037,000,000185,193,000,000140,236,000,000
Other payables68,934,000,00034,549,000,00038,515,000,0005,137,000,000
Accrued expenses0000
Short-term debt245,952,000,000282,867,000,000487,222,000,00088,546,000,000
Capital lease obligations (current)0000
Tax payables0038,515,000,0005,137,000,000
Deferred revenue0000
Other current liabilities703,763,000,000657,157,000,000574,795,000,000492,115,000,000
Total current liabilities1,218,401,000,0001,061,610,000,0001,285,725,000,000726,034,000,000
Long-term debt320,000,000,000564,893,000,000447,738,000,00050,000,000,000
Capital lease obligations (non-current)089,326,000,00070,756,000,00061,461,000,000
Deferred revenue (non-current)0000
Deferred tax liabilities (non-current)1,275,000,0005,353,000,00051,346,000,0006,048,000,000
Other non-current liabilities196,482,000,000105,108,000,000118,051,000,000105,021,000,000
Total non-current liabilities517,757,000,000764,680,000,000687,891,000,000222,530,000,000
Other liabilities0000
Capital lease obligations089,326,000,00070,756,000,00061,461,000,000
Total liabilities1,736,158,000,0001,826,290,000,0001,973,616,000,000948,564,000,000
Treasury stock-34,945,000,000-37,524,000,000-33,783,000,000-25,123,000,000
Preferred stock0000
Common stock103,001,000,000103,001,000,000103,001,000,000103,001,000,000
Retained earnings902,836,000,000740,939,000,000809,400,000,000908,158,000,000
Additional paid-in capital185,162,000,000185,259,000,000184,070,000,000181,280,000,000
Accumulated other comprehensive income/loss672,989,000,000521,580,000,000533,301,000,000340,639,000,000
Other stockholders' equity1,841,000,0000-1,000,000-1,000,000
Total stockholders' equity1,830,884,000,0001,513,255,000,0001,595,988,000,0001,507,954,000,000
Total equity1,830,884,000,0001,513,255,000,0001,595,988,000,0001,507,954,000,000
Minority interest0000
Total liabilities and total equity3,567,042,000,0003,339,545,000,0003,569,604,000,0002,456,518,000,000
Total investments158,593,000,000143,637,000,000144,421,000,000134,748,000,000
Total debt565,952,000,000937,086,000,0001,005,716,000,000200,007,000,000
Net debt284,347,000,000748,714,000,000670,029,000,000-176,833,000,000

Astellas Pharma Inc. Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/03/202631/03/202531/03/202431/03/2023
Cash from operations566,251,000,000201,613,000,000181,325,000,000332,325,000,000
Cash from investing-72,785,000,000-96,520,000,000-854,652,000,000-89,058,000,000
Cash from financing-404,779,000,000-261,367,000,000614,060,000,000-195,623,000,000
Net change in cash93,233,000,000-147,315,000,000-41,153,000,00060,854,000,000

All line items

Line item31/03/202631/03/202531/03/202431/03/2023
Net income291,535,000,00050,747,000,00017,045,000,00098,714,000,000
Depreciation and amortization194,594,000,000199,132,000,000157,840,000,000105,738,000,000
Deferred income tax0000
Stock-based compensation0000
Change in working capital27,385,000,000-147,747,000,000-51,702,000,00073,980,000,000
Accounts receivable-63,794,000,000-104,735,000,000-55,948,000,000-4,849,000,000
Inventory-16,218,000,000-50,225,000,000-60,036,000,000-7,086,000,000
Accounts payable-307,000,000-11,409,000,00029,466,000,000-12,274,000,000
Other working capital107,704,000,00018,622,000,00034,816,000,00098,189,000,000
Other non-cash items52,737,000,00099,481,000,00058,142,000,00053,893,000,000
Net cash from operating activities566,251,000,000201,613,000,000181,325,000,000332,325,000,000
Investments in property, plant and equipment-84,645,000,000-57,330,000,000-82,497,000,000-88,541,000,000
Acquisitions (net)00-784,974,000,0000
Purchases of investments0000
Sales/maturities of investments012,920,000,000012,624,000,000
Other investing activities11,860,000,000-52,110,000,00012,819,000,000-13,141,000,000
Net cash from investing activities-72,785,000,000-96,520,000,000-854,652,000,000-89,058,000,000
Net debt issuance-267,418,000,000-88,522,000,000771,233,000,000-15,000,000,000
Long-term net debt issuance-81,793,000,000147,927,000,000446,896,000,0000
Short-term net debt issuance-185,625,000,000-236,449,000,000324,337,000,000-15,000,000,000
Net stock issuance-730,000,000-6,960,000,000-10,735,000,000-60,556,000,000
Net common stock issuance-730,000,000-6,960,000,000-10,735,000,000-60,556,000,000
Common stock issuance0000
Common stock repurchased-730,000,000-6,960,000,000-10,735,000,000-60,556,000,000
Net preferred stock issuance0000
Net dividends paid-136,099,000,000-128,993,000,000-116,653,000,000-100,355,000,000
Common dividends paid-136,099,000,000-128,993,000,000-116,653,000,000-100,355,000,000
Preferred dividends paid0000
Other financing activities-532,000,000-36,892,000,000-29,785,000,000-19,712,000,000
Net cash from financing activities-404,779,000,000-261,367,000,000614,060,000,000-195,623,000,000
Effect of FX changes on cash4,546,000,0008,959,000,00018,114,000,00013,210,000,000
Net change in cash93,233,000,000-147,315,000,000-41,153,000,00060,854,000,000
Cash at end of period281,605,000,000188,372,000,000335,687,000,000376,840,000,000
Cash at beginning of period188,372,000,000335,687,000,000376,840,000,000315,986,000,000
Operating cash flow566,251,000,000201,613,000,000181,325,000,000332,325,000,000
Capital expenditure-57,723,000,000-37,003,000,000-38,056,000,000-36,441,000,000
Free cash flow508,528,000,000164,610,000,000143,269,000,000295,884,000,000
Income taxes paid0000
Interest paid0000